ClinicalTrials.gg
TerminatedNCT02533570Updated Jun 11, 2018Results posted

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

A Phase 2 interventional study of Brentuximab vedotin and Placebo in Systemic Lupus Erythematosus, sponsored by Seagen Inc.. Terminated at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-11.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on portfolio prioritization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
317th of 407
20 · median 70
Started
2015
with 16 others
Phase 2
120 of 477
10 open now
Registered
205th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 317th largest by enrollment of the 407 interventional ones that give a count, is one of 17 that started in 2015, is one of 120 in phase 2, and was the 205th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of brentuximab vedotin in adults with active systemic lupus erythematosus (SLE).

Read the detailed description

Systemic lupus erythematosus (SLE) is a chronic, multisystem, disabling autoimmune condition, which predominantly affects women of childbearing years. Treatment options for SLE remain relatively limited. Regardless of the specific therapy chosen, the majority of patients continue to require long term immunomodulatory or cytotoxic therapy, resulting in long-term morbidity and mortality. Brentuximab vedotin is an antibody-drug conjugate (ADC) consisting of: 1) the chimeric immunoglobulin (Ig) G1 antibody cAC10, specific for human CD30, 2) the microtubule disrupting agent monomethyl auristatin E (MMAE), and 3) a protease-cleavable linker that covalently attaches MMAE to cAC10. Since CD30 and/or CD30-expressing immune cells may play significant key roles in the pathogenesis of SLE, brentuximab vedotin may be an efficacious therapy. This study intends to explore the potential for brentuximab vedotin as a therapy for SLE.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Lupus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years
  • Diagnosis of SLE for at least 6 months prior to screening
  • Active SLE as indicated by SLE Disease Activity Index (SLEDAI) ≥ 4 at screening
  • Must have failed a treatment for SLE after a trial of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • The subject has any serious health condition, which, in the opinion of the Investigator, would place the subject at undue risk from the study
  • Subject has had recent serious or ongoing infection, or risk for serious infection
  • Subject has a history of new or recurrent within the past 5 years
  • The subject is pregnant and/or breastfeeding
  • The subject fulfills diagnostic criteria for another rheumatic (overlap) disease that may confound clinical assessments in the study
  • The subject has urgent, severe SLE disease activity, which, in the opinion of the Investigator, warrants immediate therapy and would not be appropriate for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Brentuximab vedotin

    4 dose groups

    Drug: Brentuximab vedotin

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Subjects Having an Adverse Event (AE)

    Any treatment-emergent adverse events (TEAEs), any drug-related TEAEs, any SAEs, treatment-related serious adverse events (SAE), deaths, adverse events (AEs) leading to study discontinuation, and number of patients experiencing Grade 1, 2, and 3 TEAEs.

    Time frame: Up to 127 days (9 weeks after final dose)

Secondary outcomes

  1. Proportion of Subjects Achieving an SRI Response at Day 85

    Assessment for response was made using data only for the visit of interest (Day 85), without regard for changes at prior on-treatment visits. SRI: SLE Responder Index; SLE: Systemic lupus erythematosus

    Time frame: 85 days

07

Results

Posted Jun 11, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kg
Started488
Completed477
Not completed011
Withdrew: Adverse event011

Outcome measures

PrimaryNumber and Percentage of Subjects Having an Adverse Event (AE)

Any treatment-emergent adverse events (TEAEs), any drug-related TEAEs, any SAEs, treatment-related serious adverse events (SAE), deaths, adverse events (AEs) leading to study discontinuation, and number of patients experiencing Grade 1, 2, and 3 TEAEs.

Time frame:
Up to 127 days (9 weeks after final dose)
Reported as:
Count of participants · Participants
Number and Percentage of Subjects Having an Adverse Event (AE)
ParticipantsPlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kg
Treatment-Emergent Adverse Event368
Treatment-Related Adverse Event031
Serious Adverse Event011
Treatment-Related Serious Adverse Events010
Deaths000
Adverse Events Leading to Study Discontinuation011
Any Grade 1 Adverse Event262
Any Grade 2 Adverse Event247
Any Grade 3 Adverse Event012
SecondaryProportion of Subjects Achieving an SRI Response at Day 85

Assessment for response was made using data only for the visit of interest (Day 85), without regard for changes at prior on-treatment visits. SRI: SLE Responder Index; SLE: Systemic lupus erythematosus

Time frame:
85 days
Reported as:
Count of participants · Participants
Proportion of Subjects Achieving an SRI Response at Day 85
ParticipantsPlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kg
Proportion of Subjects Achieving an SRI Response at Day 85012

Adverse events

Collected over Up to 127 days (9 weeks after last dose). The safety reporting period for all AEs and SAEs is from the date of consent through the follow-up visit. All SAEs that occur after the safety reporting period and are considered study treatment-related in the opinion of the Investigator should also be reported to the Sponsor. Additionally, new-onset neuropathy, suspected PML, or other AEs/SAEs of interest are reported until the end of the follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/4 (0%)0/4 (0%)3/4 (75%)
Brentuximab Vedotin 0.3 mg/kg0/8 (0%)1/8 (12.5%)6/8 (75%)
Brentuximab Vedotin 0.6 mg/kg0/8 (0%)1/8 (12.5%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kg
ConcussionInjury, poisoning and procedural complications0/40/81/8
DyspnoeaRespiratory, thoracic and mediastinal disorders0/41/80/8
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kg
DizzinessNervous system disorders0/43/80/8
NauseaGastrointestinal disorders0/42/80/8
MalaiseGeneral disorders1/40/80/8
Flank PainMusculoskeletal and connective tissue disorders1/40/81/8
ArthritisMusculoskeletal and connective tissue disorders1/40/80/8
Limb DiscomfortMusculoskeletal and connective tissue disorders1/40/80/8
DepressionPsychiatric disorders1/40/80/8
AlopeciaSkin and subcutaneous tissue disorders1/40/81/8
Dermal CystSkin and subcutaneous tissue disorders1/40/80/8
UrticariaSkin and subcutaneous tissue disorders1/40/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kgTotal
Mean45.5 ± 8.6650.8 ± 14.0645.0 ± 11.2047.4 ± 11.78
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kgTotal
Female48820
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kgTotal
Hispanic or Latino1034
Not Hispanic or Latino38516
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kgTotal
American Indian or Alaska Native0101
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1157
White36312
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)PlaceboBrentuximab Vedotin 0.3 mg/kgBrentuximab Vedotin 0.6 mg/kgTotal
United States48820
08

Study locations

17 sites
  • University of Alabama at Birmingham - (UAB)
    Birmingham, Alabama 35294, United States
  • TriWest Research Associates, LLC
    El Cajon, California 92020-4124, United States
  • Advanced Medical Research, LLC
    La Palma, California 90623, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Clinical Research of West Florida - Corporate
    Clearwater, Florida 33765, United States
  • Lakes Research, LLC
    Miami Lakes, Florida 33014, United States
  • Arthritis Associates
    Orlando, Florida 32804, United States
  • McIlwain Medical Group
    Tampa, Florida 33613, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Clayton Medical Associates, P.C.
    Saint Louis, Missouri 63117, United States
  • Weill Cornell Physicians at Brooklyn Heights
    Brooklyn, New York 11201, United States
  • DJL Clinical Research, PLLC
    Charlotte, North Carolina 28210, United States
  • Arthritis & Rheumatology Center of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Ramesh C Gupta MD
    Memphis, Tennessee 38119, United States
  • Tekton Research, Inc.
    Austin, Texas 78745, United States
  • Accurate Clinical Research
    Houston, Texas 77034, United States
  • Arthritis Clinic of Northern Virginia, PC
    Arlington, Virginia 22205-3606, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2015
First posted
Aug 27, 2015
Start
Jul 2015
Primary completionActual
Jun 5, 2017
CompletionActual
Jun 5, 2017
Results first posted
Jun 11, 2018
Last update
Jun 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02533570
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Aug 27, 2015
Start date
Jul 2015
Primary completion
Jun 5, 2017
Completion
Jun 5, 2017
Results posted
Jun 11, 2018
Last update
Jun 11, 2018

Study contacts

Steve Sesterhenn, MD
study director · Seattle Genetics Medical Monitor

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion